IP Library Patent Application 14735046
Patent Application
App. No. 14/735,046

METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/735,046
Abstract

The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.

Claims (24)

1 . A method of treating cancer in an individual in need thereof, comprising administering to the individual a therapeutically-effective amount of a composition comprising a synthetic miRNA comprising: an active strand consisting of 7 to 30 nucleosides and 100% identical to nucleobases 23-28 of SEQ ID NO: 58.

2 . (canceled)

3 . (canceled)

4 . A composition, comprising: a synthetic miRNA comprising:

(a) an active strand consisting of 7 to 30 nucleosides and 100% identical to nucleobases 23-28 of SEQ ID NO: 58; and

(b) complementary strand at least 60% complementary to the miRNA region.

5 . The composition of claim 4 , wherein the complementary strand comprises a 5′ terminus cap.

6 . (canceled)

7 . (canceled)

8 . The composition of claim 4 , wherein the complementary strand is at least 90% complementary to the miRNA region.

9 . The composition of claim 4 , wherein the complementary strand is 100% complementary to the miRNA region.

10 . The composition of claim 4 , wherein the complementary strand further comprises a sugar modification in the first or last 1-6 residues.

11 . The composition of claim 10 , wherein the sugar modification is a 2′-O-methyl modification.

12 . A composition, comprising: a synthetic miRNA, comprising:

(a) an active strand consisting of 19-23 nucleosides and at least 90% identical to the sequence of SEQ ID NO: 58; and

(b) a complementary strand consisting of 19-23 nucleosides and complementary to the active strand.

13 . The composition of claim 12 , wherein the active strand comprises a sequence 100% identical to the sequence of SEQ ID NO: 58.

14 . The composition of claim 12 , further comprising a lipid.

15 . The composition of claim 12 , wherein the complementary strand comprises a 5′ terminus cap.

16 . The composition of claim 12 , wherein the complementary strand is at least 90% complementary to the miRNA region.

17 . The composition of claim 12 , wherein the complementary strand is 100% complementary to the miRNA region.

18 . The composition of claim 12 , wherein the complementary strand further comprises a sugar modification in the first or last 1-6 residues.

19 . The composition of claim 12 , wherein the sugar modification is a 2′-O-methyl modification.

20 . The method of claim 1 , wherein the synthetic miRNA further comprises a complementary strand at least 60% complementary to the miRNA region.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2015
From: BROWN, DAVID; FORD, LANCE; CHENG, ANGIE; JARVIS, RICH; BYROM, MIKE; OVCHARENKO, DMITRIY; DEVROE, ERIC; KELNAR, KEVIN
To: AMBION, INC.
Reel/Frame 035973/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2015
From: AMBION, INC.
To: APPLERA CORPORATION
Reel/Frame 035973/0296 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2015
From: APPLERA CORPORATION
To: ASURAGEN, INC.
Reel/Frame 035973/0380 →